kneat.com (KSI) AI Stock Analysis

• Market Cap: C$523.67M
• Dividend Yield: N/A
• Average Volume (3M): 120.08K
• Price to Earnings (P/E): 1018.5
• Beta (1Y): 1.15
• Revenue Growth: 39.32%
• EPS Growth: N/A
• Country: CA
• Employees: 297
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.00
• Shares Outstanding: 95,212,166
• 10 Day Avg. Volume: 105,937
• 30 Day Avg. Volume: 120,085
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$7.83
• Price Target Upside: 48.86% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 61 Neutral
• Price Target: C$6.00 ▲(14.07% Upside)

Kneat.com shows strong revenue growth and a solid gross profit margin, but profitability remains a concern with negative net profit margins. The stock's technical indicators suggest short-term bullish momentum, but the extremely high P/E ratio indicates potential overvaluation. The earnings call provided positive insights into growth and innovation, although challenges such as increased expenses and FX impacts were noted. Overall, the company is on a positive trajectory but needs to address profitability and valuation concerns to improve its financial position.

kneat.com Business Overview & Revenue Model

Company Description

Kneat.com (KSI) is a leading provider of software solutions designed to streamline and automate the validation processes in regulated industries such as pharmaceuticals, biotechnology, and medical devices. Its flagship product, Kneat GxP, offers an innovative platform that enhances efficiency, compliance, and quality management by facilitating electronic document management and validation workflows. The company operates primarily in the life sciences sector, focusing on helping organizations achieve regulatory compliance and operational excellence.

How the Company Makes Money

Kneat.com generates revenue primarily through a subscription-based model, where clients pay for access to its software solutions on a recurring basis. This includes annual licensing fees for the Kneat GxP platform, which vary based on the scale of implementation and the number of users. Additionally, the company earns revenue from professional services, which can include implementation support, training, and consulting services to help clients optimize their use of the software. Key partnerships with industry leaders and regulatory bodies also enhance Kneat's credibility and market reach, contributing to its earnings by attracting a larger client base seeking reliable compliance solutions.

kneat.com Financial Statement Overview

Summary

kneat.com shows strong revenue growth and a solid balance sheet, but ongoing losses and negative margins due to high expenses are concerning. Cash flow management is improving, but free cash flow remains negative.

Income Statement

kneat.com has demonstrated consistent revenue growth over recent years, with a notable increase of 8.14% in the TTM period compared to the previous year. However, the company is struggling with profitability, as evidenced by its negative EBIT and net profit margins, indicating that expenses are significantly impacting the bottom line.

Balance Sheet

The balance sheet reflects a solid equity position with a debt-to-equity ratio of 0.37, indicating moderate leverage and financial stability. The equity ratio is relatively strong at 48.9%, suggesting that the company is well-capitalized. However, the company must manage its liabilities effectively to maintain this balance.

Cash Flow

Cash flow analysis reveals positive operating cash flow, which is a good indicator of internal cash generation. However, free cash flow remains negative, highlighting challenges in covering capital expenditures. The company shows improvement in cash flow management, but further efficiency is necessary to enhance free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	56.65M	48.94M	34.22M	23.75M	15.50M	7.42M
Gross Profit	42.68M	36.76M	23.13M	14.65M	9.32M	2.88M
EBITDA	16.02M	6.27M	-5.77M	-3.20M	-5.11M	-2.30M
Net Income	476.72K	-7.73M	-14.12M	-9.15M	-9.86M	-5.88M
Balance Sheet
Total Assets	134.67M	124.58M	64.50M	50.41M	51.28M	33.80M
Cash, Cash Equivalents and Short-Term Investments	66.77M	58.89M	15.25M	12.28M	21.56M	8.66M
Total Debt	30.66M	29.26M	28.17M	7.09M	7.86M	9.52M
Total Liabilities	68.29M	59.51M	49.73M	24.43M	17.09M	14.59M
Stockholders Equity	66.38M	65.07M	14.76M	25.98M	34.19M	19.21M
Cash Flow
Free Cash Flow	-5.54M	-10.09M	-18.39M	-9.82M	-7.74M	-9.28M
Operating Cash Flow	15.31M	9.79M	-1.28M	2.99M	2.31M	-1.98M
Investing Cash Flow	-18.94M	-17.52M	-15.97M	-11.91M	-10.04M	-6.43M
Financing Cash Flow	30.23M	50.62M	20.27M	-383.91K	21.20M	13.11M

kneat.com Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KSI, the sentiment is Negative. The current price of 5.26 is below the 20-day moving average (MA) of 5.70, below the 50-day MA of 5.59, and below the 200-day MA of 6.08, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 35.25 is Neutral, neither overbought nor oversold. The STOCH value of 15.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:KSI.

kneat.com Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VHI	―	C$636.03M	113.06	3.23%	―	41.68%	-16.15%
KSI	―	C$523.67M	1,018.52	0.99%	―	39.32%	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADK	―	C$35.14M	-6.98	―	―	-47.10%	-19.32%
AIML	―	C$11.63M	-1.61	-1143.80%	―	-64.23%	18.42%
UDOC	―	$14.89M	-2.48	―	―	―	21.61%
AIDR	―	C$69.93M	―	-202.19%	―	―	40.17%

kneat.com Corporate Events

Kneat to Release Q3 2025 Financial Results

Kneat.com announced it will release its third-quarter financial results for 2025 on November 12, following the close of the TSX market. The announcement highlights Kneat’s continued focus on transparency and engagement with stakeholders, as the company plans a webcast conference call for analysts the following day. This release is part of Kneat’s ongoing efforts to maintain its leadership in the digital validation industry, providing stakeholders with insights into its financial performance and strategic direction.

The most recent analyst rating on (TSE:KSI) stock is a Hold with a C$6.00 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat Secures Major Agreement to Enhance Digital Transformation for Global Manufacturer

Kneat.com has entered into a Master Services Agreement with a leading multinational manufacturer to implement its Kneat Gx platform for digital transformation across enterprise applications and manufacturing sites. This strategic partnership underscores Kneat’s ability to enhance compliance, efficiency, and scalability in validation processes, further solidifying its position as a preferred platform in the life sciences sector.

The most recent analyst rating on (TSE:KSI) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat.com Leads G2 Pharma and Biotech Software Rankings

Kneat.com has been recognized as a leader in G2’s Fall 2025 Pharma and Biotech Software category reports, achieving top positions in three categories. The company’s high G2 Satisfaction Score of 98 reflects strong customer satisfaction and market presence, highlighting its impact in the life sciences industry.

The most recent analyst rating on (TSE:KSI) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat Solutions to Showcase Innovations at Emerging Growth Conference

Kneat Solutions announced its participation in the Emerging Growth Conference on September 24, 2025, where CEO Eddie Ryan will present the company’s recent progress and engage with investors in a live, interactive session. This event highlights Kneat’s ongoing commitment to innovation in digital validation, reinforcing its position as a key player in the life sciences industry by providing solutions that reduce risk and accelerate product market entry.

The most recent analyst rating on (TSE:KSI) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat Secures Strategic Agreement with Leading Equipment Manufacturer

Kneat.com has secured a three-year Master Services Agreement with a major European equipment manufacturer, marking its seventh strategic customer win in 2025. This agreement will see the implementation of the Kneat Gx platform to digitize the manufacturer’s equipment testing processes, enhancing quality and client handover, and is part of Kneat’s ongoing success in expanding digital capabilities across industries.

The most recent analyst rating on (TSE:KSI) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat.com Earnings Call Highlights Strong Growth and Strategic Wins

Kneat.com, Inc. recently held its earnings call, showcasing a strong performance characterized by significant revenue and annual recurring revenue (ARR) growth. The positive sentiment was driven by strategic customer wins and product enhancements, although challenges such as increased operating expenses and foreign exchange impacts were acknowledged. The company remains focused on strategic growth and innovation, positioning itself well despite these hurdles.

Kneat Secures Major Agreement with Global Medical Tech Leader

Kneat.com has secured a three-year Master Services Agreement with a major global medical technology company, a division of a larger Asian manufacturer. This agreement will see the implementation of Kneat’s Gx platform for equipment validation, further solidifying Kneat’s position in the life sciences sector. The adoption by large-scale life sciences companies highlights Kneat’s technical capabilities and the strategic trust placed in their platform.

The most recent analyst rating on (TSE:KSI) stock is a Buy with a C$4.90 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat.com Reports Record Q2 2025 Revenue and Strategic Growth

Kneat.com announced a record revenue of $15.4 million for the second quarter of 2025, marking a 32% increase from the previous year. The company’s gross margin reached 75%, and its annual recurring revenue grew by 43% to $64.8 million. These financial results highlight Kneat’s strong market position and the growing adoption of its Kneat Gx platform. The company has also expanded its executive leadership team and secured significant agreements with multinational companies, further solidifying its presence in the industry.

The most recent analyst rating on (TSE:KSI) stock is a Buy with a C$4.90 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat to Release Q2 2025 Financial Results

Kneat.com announced it will release its second-quarter financial results for 2025 on August 5, after the TSX market closes. The announcement will be followed by a conference call with key executives on August 6, aimed at providing insights to sell-side analysts. This release is significant for stakeholders as it reflects Kneat’s ongoing commitment to transparency and could impact its market positioning.

The most recent analyst rating on (TSE:KSI) stock is a Buy with a C$4.90 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.